NewAmsterdam Pharma Ownership

NAMS Stock

23.87 0.20 0.83%

NewAmsterdam Pharma maintains a total of 109.82 Million outstanding shares. The majority of NewAmsterdam Pharma outstanding shares are owned by institutional investors. These third-party entities are usually referred to as non-private investors looking to shop for positions in NewAmsterdam Pharma to benefit from reduced commissions. Consequently, institutional holders are subject to a different set of regulations than regular investors in NewAmsterdam Pharma. Please pay attention to any change in the institutional holdings of NewAmsterdam Pharma as this could imply that something significant has changed or is about to change at the company. Please note that no matter how many assets the company has, if the real value of the firm is less than the current market value, you may not be able to make money on it.

Please note, institutional investors have a lot of resources and new technology at their disposal. They can put in a lot of research and financial analysis when reviewing investment options. There are many different types of institutional investors, including banks, hedge funds, insurance companies, and pension plans. One of the main advantages they have over retail investors is the fees paid for trades. As they are buying in large quantities, they can manage their cost more effectively.

Check out Correlation Analysis to better understand how to build diversified portfolios, which includes a position in NewAmsterdam Pharma. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in population.

For more information on how to buy NewAmsterdam Stock please use our How to Invest in NewAmsterdam Pharma guide.

NewAmsterdam Stock Ownership Analysis

About 99.0% of the company shares are owned by institutional investors. The book value of NewAmsterdam Pharma was now reported as 7.01. The company recorded a loss per share of 2.56. NewAmsterdam Pharma had not issued any dividends in recent years. The entity had 1:1 split on the 23rd of November 2022. To find out more about NewAmsterdam Pharma contact FACC Facp at 31 35 206 2971 or learn more at https://www.newamsterdampharma.com.

NewAmsterdam Pharma Insider Trading Activities

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific NewAmsterdam Pharma insiders, such as employees or executives, is commonly permitted as long as it does not rely on NewAmsterdam Pharma's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases NewAmsterdam Pharma insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.

		Douglas Kling few days ago Disposition of 100000 shares by Douglas Kling of NewAmsterdam Pharma at 23.16 subject to Rule 16b-3
		Louise Kooij over two weeks ago Disposition of 150000 shares by Louise Kooij of NewAmsterdam Pharma at 20.37 subject to Rule 16b-3
		Douglas Kling over two weeks ago Disposition of 8914 shares by Douglas Kling of NewAmsterdam Pharma at 21.33 subject to Rule 16b-3
		Douglas Kling over a month ago Disposition of 9218 shares by Douglas Kling of NewAmsterdam Pharma at 19.23 subject to Rule 16b-3
		Douglas Kling over a month ago Disposition of 90782 shares by Douglas Kling of NewAmsterdam Pharma at 19.54 subject to Rule 16b-3
		Douglas Kling over a month ago Disposition of 13578 shares by Douglas Kling of NewAmsterdam Pharma subject to Rule 16b-3
		Douglas Kling over a month ago Disposition of 5148 shares by Douglas Kling of NewAmsterdam Pharma at 21.93 subject to Rule 16b-3
		Douglas Kling over a month ago Disposition of 23815 shares by Douglas Kling of NewAmsterdam Pharma at 23.46 subject to Rule 16b-3
		Van Der Kamp Hilde Johanna over a month ago Acquisition by Van Der Kamp Hilde Johanna of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3
		Smither John W over two months ago Acquisition by Smither John W of 6960 shares of NewAmsterdam Pharma subject to Rule 16b-3
		Mayur Somaiya over two months ago Acquisition by Mayur Somaiya of 38000 shares of NewAmsterdam Pharma subject to Rule 16b-3
		Davidson Michael H. over two months ago Acquisition by Davidson Michael H. of 670467 shares of NewAmsterdam Pharma at 25.85 subject to Rule 16b-3

NewAmsterdam Pharma Outstanding Bonds

NewAmsterdam Pharma issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. NewAmsterdam Pharma uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most NewAmsterdam bonds can be classified according to their maturity, which is the date when NewAmsterdam Pharma has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.

	Dana 575 percent Corp Bond US235822AB96	View
	MPLX LP 4125 Corp Bond US55336VAK61	View
	MPLX LP 4875 Corp Bond US55336VAJ98	View
	MPLX LP 52 Corp Bond US55336VAL45	View
	Morgan Stanley 3591 Corp Bond US61744YAK47	View
	Morgan Stanley 3971 Corp Bond US61744YAL20	View
	MGM Resorts International Corp Bond US552953CD18	View
	Valero Energy Partners Corp Bond US91914JAA07	View

View All NewAmsterdam Pharma Corporate Bonds

Thematic Opportunities

Explore Investment Opportunities

Build portfolios using Macroaxis predefined set of investing ideas. Many of Macroaxis investing ideas can easily outperform a given market. Ideas can also be optimized per your risk profile before portfolio origination is invoked. Macroaxis thematic optimization helps investors identify companies most likely to benefit from changes or shifts in various micro-economic or local macro-level trends. Originating optimal thematic portfolios involves aligning investors' personal views, ideas, and beliefs with their actual investments.

Explore Investing Ideas

Additional Tools for NewAmsterdam Stock Analysis

When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC